menu
    • menu
    [{"orgOrder":0,"company":"Novotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Panaphix","moa":"Cytokine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Novotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/ Not Applicable"},{"orgOrder":0,"company":"Novotech","sponsor":"CytoAgents","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"XW003","moa":"Glucagon secretion","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Novotech \/ Skye Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novotech \/ Skye Bioscience"},{"orgOrder":0,"company":"Novotech","sponsor":"OliPass","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Invivyd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"PAS-004","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Novotech

    Menu

    Novotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAS-004

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Pasithea Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pasithea Therapeutics Opens Enrollment in the U.S. for Phase 1 Trial of PAS-004

                            Details : PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.

                            Brand Name : PAS-004

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 13, 2024

                            Lead Product(s) : PAS-004

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Pasithea Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VYD222

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Invivyd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On ...

                            Details : VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.

                            Brand Name : VYD222

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 26, 2023

                            Lead Product(s) : VYD222

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Invivyd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : OliPass

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002

                            Details : OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.

                            Brand Name : OLP-1002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : OliPass

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ifenprodil Tartrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Recipient : Algernon Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary ...

                            Details : In the study NP-120 (Ifenprodil), demonstrated 65% of patients had stable or improved forced vital capacity (“FVC”) over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%.

                            Brand Name : NP-120

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : Ifenprodil Tartrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Recipient : Algernon Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

                            Details : SBI-100, a proprietary prodrug of tetrahydrocannabinol (“THC”), is a topical formulation under development to treat glaucoma. SBI-100 enables enhanced local delivery of the drug into the eye, reduced systemic side effects and the potential for neurop...

                            Brand Name : SBI-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 03, 2022

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Hoth Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underw...

                            Details : The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate...

                            Brand Name : BioLexa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2021

                            Lead Product(s) : Gentamicin Sulfate,Pentetic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Hoth Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XW003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Recipient : Sciwind Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sciwind's Investigational New Drug Approved for NASH Trial

                            Details : XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.

                            Brand Name : XW003

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 28, 2021

                            Lead Product(s) : XW003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Recipient : Sciwind Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : CytoAgents

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CytoAgents Launches Clinical Trials for GP1681, Treatment of COVID-19 Cytokine Storm

                            Details : The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.

                            Brand Name : GP1681

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : CytoAgents

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Novotech

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panaphix

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea

                            Details : The company said it seeks to expand the use of Panaphix to cover COVID-19 treatment through this proposed clinical trial.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            March 06, 2020

                            Lead Product(s) : Panaphix

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth